Abbott (ABT)
Makes glucose monitors, cardiovascular devices, diagnostic tests, nutrition products, and branded generic medicines.
Something off on this page? Send us feedback.
Sells medical devices, diagnostic systems and tests, nutritional products, and branded generic medicines to healthcare providers and consumers worldwide. Medical Devices—anchored by FreeStyle Libre and cardiovascular platforms—is the largest business, while most sales come from outside the United States.
Develops and sells products across Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. The largest segment and recent growth engine combines FreeStyle Libre continuous glucose monitoring with cardiovascular and neuromodulation platforms. Diagnostics spans Alinity laboratory systems, rapid and point-of-care tests, and cancer screening and precision-oncology testing added through Exact Sciences.
Nutrition includes Similac infant formula, Ensure and Glucerna adult nutrition, and Pedialyte. Established Pharmaceuticals markets branded generic medicines only outside the United States, principally in emerging markets.
Most sales come from outside the United States. Products face comprehensive regulation covering development, approval, manufacturing, labeling, pricing, reimbursement, and post-market surveillance, while overseas sales create foreign-exchange and trade-policy exposure.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Wolfe Research | Reiterate | Rating: —Target: — | Target: $130 |
| Jul 28, 2026 | UBS | Reiterate | Rating: —Target: $115 | Target: $125 |
| Jul 20, 2026 | Benchmark Co. | Target | Target: — | Target: $120 |
| Jul 17, 2026 | Piper Sandler | Reiterate | Rating: —Target: $115 | Target: $118 |
| Jul 16, 2026 | BTIG | Target | Target: $145 | Target: $134 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.60B · Total debt $32.61B · Total assets $109.22B · Shareholders' equity $51.11B
- Revenue
- $12.59B
- Operating income
- $1.78B
- Net income
- $928.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 83.08% | 1.44B shares | |
|---|---|---|---|
| 3,063 holders · as of Jun 30, 2026 | |||
| Insiders | 0.11% | 1.87M shares | |
| 25 holders · as of Sep 3, 2026 | |||
| Other | 16.81% | 290.95M shares | |
| remainder | |||
1.73B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.82% | 152.56M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.57% | 113.75M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.68% | 80.93M | as of Jun 30, 2026 |
Charles Schwab Investment Management IncInstitution | 3.45% | 59.67M | as of Jun 30, 2026 |
Sixth Street Partners Management Company, L.P.Institution | 3.45% | 59.67M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | John A. Jr. Mccoy | officer: VICE PRESIDENT AND CONTROLLER | −27 | $109.54 |
| Aug 25, 2026 | Robert B. Ford | director, officer: CHAIRMAN AND CEO | −398,832 | $115.85 |
| Aug 11, 2026 | Louis H. Morrone | officer: EXECUTIVE VICE PRESIDENT | −5,850 | $109.83 |
| May 7, 2026 | John G. Stratton | director | +2,000 | $86.82 |
| Apr 27, 2026 | Daniel J. Starks | director | +10,000 | $92.65 |
- Medtronic
Broadest overlap: CGM, cardiac rhythm, structural heart, neuromodulation, and EP
- Boston Scientific
Competes in EP mapping, coronary stents, structural heart, CRM, and neuromod
- Dexcom
Head-to-head CGM rival in intensive insulin mgmt and OTC glucose biosensors
- Danaher
Diagnostics conglomerate: Cepheid POC, Radiometer blood gas, Beckman core lab
- Edwards Lifesciences
Structural heart (TAVR, mitral repair) and hemodynamic monitoring overlap
- BD
Rapid POC antigen, molecular syndromic panels, and microbiology overlap
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abbott | $103.69 | −0.03% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Medtronic | $90.77 | 0.00% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Boston Scientific | $44.98 | +0.10% | $64.98B | 17.8 | 13.7 | 3.1 | +7.5% |
| Dexcom | $90.00 | +0.54% | $33.65B | 35.2 | 31.9 | 6.8 | +13.1% |
| Danaher | $220.87 | −0.11% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Edwards Lifesciences | $88.78 | −0.02% | $50.87B | 50.8 | 28.3 | 7.8 | +13.6% |
| BD | $183.00 | −0.03% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Median | 36.8 | 20.1 | 4.6 | +10.3% |